Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by First Business Financial Services Inc.

First Business Financial Services Inc. raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 8.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,560 shares of the medical research company’s stock after purchasing an additional 200 shares during the quarter. First Business Financial Services Inc.’s holdings in Thermo Fisher Scientific were worth $1,584,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. CIBC Asset Management Inc increased its stake in Thermo Fisher Scientific by 2.6% during the third quarter. CIBC Asset Management Inc now owns 245,713 shares of the medical research company’s stock worth $151,914,000 after purchasing an additional 6,313 shares during the period. FUKOKU MUTUAL LIFE INSURANCE Co boosted its stake in shares of Thermo Fisher Scientific by 3.3% in the 3rd quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 1,672 shares of the medical research company’s stock valued at $1,034,000 after buying an additional 53 shares during the period. Balboa Wealth Partners grew its holdings in Thermo Fisher Scientific by 59.7% during the 3rd quarter. Balboa Wealth Partners now owns 883 shares of the medical research company’s stock worth $546,000 after acquiring an additional 330 shares in the last quarter. Sycomore Asset Management increased its holdings in shares of Thermo Fisher Scientific by 71.7% in the 3rd quarter. Sycomore Asset Management now owns 15,389 shares of the medical research company’s stock valued at $9,531,000 after acquiring an additional 6,426 shares during the last quarter. Finally, Lifeworks Advisors LLC purchased a new position in shares of Thermo Fisher Scientific in the 3rd quarter valued at $225,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Redburn Atlantic started coverage on shares of Thermo Fisher Scientific in a research report on Monday, October 14th. They issued a “buy” rating and a $680.00 price target for the company. UBS Group raised Thermo Fisher Scientific to a “strong-buy” rating in a research note on Monday, September 16th. Morgan Stanley lifted their price objective on Thermo Fisher Scientific from $655.00 to $680.00 and gave the stock an “overweight” rating in a research report on Friday, September 20th. Barclays dropped their price target on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 23rd. Finally, Wells Fargo & Company decreased their price target on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $649.33.

Insider Buying and Selling

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $1,120,320.00. Following the completion of the sale, the senior vice president now directly owns 12,736 shares of the company’s stock, valued at $7,134,197.76. The trade was a 13.57 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $168,048.00. Following the completion of the transaction, the executive vice president now directly owns 16,663 shares in the company, valued at $9,333,946.08. The trade was a 1.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 37,150 shares of company stock worth $20,651,865. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $533.02 on Friday. The stock has a market cap of $203.88 billion, a price-to-earnings ratio of 33.42, a price-to-earnings-growth ratio of 3.58 and a beta of 0.79. The company has a 50-day moving average price of $589.87 and a two-hundred day moving average price of $583.04. Thermo Fisher Scientific Inc. has a 52 week low of $463.99 and a 52 week high of $627.88. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The firm had revenue of $10.60 billion for the quarter, compared to analyst estimates of $10.63 billion. During the same period in the previous year, the company earned $5.69 earnings per share. Thermo Fisher Scientific’s revenue was up .2% compared to the same quarter last year. Analysts forecast that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th will be given a $0.39 dividend. The ex-dividend date is Friday, December 13th. This represents a $1.56 annualized dividend and a dividend yield of 0.29%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.78%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.